Postural sway, falls, and self-reported neuropathy in aging female cancer survivors.

Falls were collected by asking about the previous six months, not by following participants forward, so recall and timing may affect the fall group. Neuropathy was classified from self-reported symptoms in the past week, not from objective nerve testing, so mild or subtle neuropathy may be missed. The analysis did not know the types of chemotherapy each woman received, and different chemotherapy types can have different nerve toxicity. Other balance risk factors, such as muscle wasting or vestibular toxicity, were not measured in the original trial. The sample was limited to women aged 50 to 75 who were physically inactive, ambulatory, and free of central nervous system, metastatic, or neurologic disease, so results may not apply to men, more active survivors, or people with those conditions. The sway measurements were taken while standing quietly with eyes open, so the findings may not capture balance during walking or unstable conditions. This is a baseline analysis from a randomized trial, not a test of an intervention, so it cannot show that any treatment changes sway or falls.

The supplied article metadata lists NIH extramural research support. No author conflict-of-interest declaration is provided in the text.

Do not conclude that overall sway size predicts falls in all older female cancer survivors. Across the whole survivor group, sway magnitude scores were not associated with falls. The fall association was with mediolateral sway frequency, and sway magnitude was associated with falls in survivors with neuropathy symptoms.